Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.55 |
| ▸ | DRD4 | P21917 | 3/20 | 0.54 |
| ▸ | HTR7 | P34969 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229736 | 1.00 | MAPK1 (0.55) | MAPK1SLC18A3DRD4HTR7MEN1 | |
| SCHEMBL2790387 | 0.84 | SLC18A3 (0.60) | SLC18A3DRD4HTR7DRD2DRD3 | |
| SCHEMBL2793757 | 0.84 | SLC18A3 (0.60) | SLC18A3DRD4HTR7DRD2DRD3 | |
| SCHEMBL8186075 | 0.84 | MEN1 (0.64) | MAPK1DRD4HTR7MEN1KMT2A | |
| SCHEMBL2792992 | 0.84 | SLC18A3 (0.60) | SLC18A3DRD4HTR7DRD2DRD3 | |
| SCHEMBL13229584 | 0.80 | SLC18A3 (0.81) | SLC18A3DRD4DRD2DRD3 | |
| SCHEMBL2791859 | 0.80 | SLC18A3 (0.81) | SLC18A3DRD4DRD2DRD3 | |
| SCHEMBL2792852 | 0.80 | FUCA1 (0.63) | SLC18A3ALDH1A1 | |
| SCHEMBL9225440 | 0.80 | MAPK1 (0.81) | MAPK1DRD4HTR7ADRA1DADRA1A | |
| SCHEMBL13229582 | 0.80 | FUCA1 (0.63) | SLC18A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168093-A1 | SUBSTITUTED 3-AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DE DR. ESTEVE, S.A. (ES) | 2010-07-01 | — | — | US | claimed |
| EP-2029571-A1 | SUBSTITUTED 3 -AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-03-04 | — | — | EP | claimed |
| WO-2007128460-A1 | SUBSTITUTED 3 -AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-11-15 | — | — | WO | claimed |
| US-20100168093-A1 | SUBSTITUTED 3-AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DE DR. ESTEVE, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| EP-2029571-A1 | SUBSTITUTED 3 -AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007128460-A1 | SUBSTITUTED 3 -AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168093-A1 | SUBSTITUTED 3-AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | PAH, HMBS, P4HA1 | MAPK1 4378/4885SLC18A3 1740/4885DRD4 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.